Willoughby JMT, Beckett J, Kumar PJ, Dawson AM. Controlled trial of azathioprine in Crohn’s disease. Lancet. 1971;298:944–7.

Google Scholar 

Zhang F, Gao X, Ding L, et al. Prospective evaluation of pharmacogenomics and metabolite measurements upon azathioprine therapy in inflammatory bowel disease: an observational study. Medicine (Baltimore). 2016;95:e3326.

Love BL, Smith LS, Sarbah SA, Fowler FC. Azathioprine and infliximab: monotherapy or combination therapy in the treatment of Crohn’s disease. Clin Med Gastroenterol. 2011;4:4.

Google Scholar 

Dignass A, Van Assche G, Lindsay JO, et al. The second European evidence-based consensus on the diagnosis and management of Crohn’s disease: current management. J Crohns Colitis. 2010;4:28–62.

Ooi CJ, Makharia GK, Hilmi I, et al. Asia-Pacific consensus statements on Crohn’s disease. Part 2: Management. J Gastroenterol Hepatol. 2016;31:56–68.

Yeo JQ, Cheen HHM, Wong A, et al. Clinical utility of thiopurine metabolite monitoring in inflammatory bowel disease and its impact on healthcare utilization in Singapore. JGH Open. 2022;6:658–66.

PubMed  PubMed Central  Google Scholar 

Dubinsky MC, Lamothe S, Yang HY, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology. 2000;118:705–13.

PubMed  CAS  Google Scholar 

Relling MV, Schwab M, Whirl-Carrillo M, et al. Clinical pharmacogenetics implementation consortium guideline for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 update. Clin Pharmacol Ther. 2019;105:1095–105.

Gilissen LP, Wong DR, Engels LG, et al. Therapeutic drug monitoring of thiopurine metabolites in adult thiopurine tolerant IBD patients on maintenance therapy. J Crohns Colitis. 2012;6:698–707.

PubMed  Google Scholar 

Sparrow MP. Use of allopurinol to optimize thiopurine immunomodulator efficacy in inflammatory bowel disease. Gastroenterol Hepatol (N Y). 2008;4:505–11.

PubMed  Google Scholar 

Haines ML, Ajlouni Y, Irving PM, et al. Clinical usefulness of therapeutic drug monitoring of thiopurines in patients with inadequately controlled inflammatory bowel disease. Inflamm Bowel Dis. 2011;17:1301–7.

PubMed  Google Scholar 

Sparrow MP, Hande SA, Friedman S, Cao D, Hanauer SB. Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine. Clin Gastroenterol Hepatol. 2007;5:209–14.

PubMed  CAS  Google Scholar 

Sousa P, Ministro P, Armuzzi A, et al. Thiopurines: use them or lose them? International survey on current and future use of thiopurines in inflammatory bowel disease. Dig Liver Dis. 2021;53:1571–9.

PubMed  CAS  Google Scholar 

Parkar SP, Dherai AJ, Desai DC, Ashavaid TF. Thiopurine metabolite level and toxicity in Indians with inflammatory bowel disease. JGH Open. 2017;1:25–131.

PubMed  PubMed Central  Google Scholar 

Warner B, Johnston E, Arenas-Hernandez M, et al. A practical guide to thiopurine prescribing and monitoring in IBD. Frontline Gastroenterol. 2018;9:10–5.

PubMed  CAS  Google Scholar 

Bastida G, Nos P, Aguas M, et al. Incidence, risk factors and clinical course of thiopurine-induced liver injury in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2005;22:775–82.

PubMed  CAS  Google Scholar 

van Hoeve K, Vermeire S. Thiopurines in pediatric inflammatory bowel disease: current and future place. Pediatr Drugs. 2020;22:449–61.

Google Scholar 

Ruemmele FM, Veres G, Kolho KL, et al. Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn’s disease. J Crohns Colitis. 2014;8:1179–207.

PubMed  CAS  Google Scholar 

Feuerstein JD, Nguyen GC, Kupfer SS, et al. American gastroenterological association institute guideline on therapeutic drug monitoring in inflammatory bowel disease. Gastroenterology. 2017;153:827–34.

Vande Casteele N, Herfarth H, Katz J, Falck-Ytter Y, Singh S. American Gastroenterological Association Institute Technical Review on the role of therapeutic drug monitoring in the management of inflammatory bowel diseases. Gastroenterology. 2017;153:835–57.e6.

Dubinsky MC. Azathioprine, 6-mercaptopurine in inflammatory bowel disease: pharmacology, efficacy, and safety. Clin Gastroenterol Hepatol. 2004;2:731–43.

PubMed  CAS  Google Scholar 

Ooi CY, Bohane TD, Lee D, Naidoo D, Day AS. Thiopurine metabolite monitoring in paediatric inflammatory bowel disease. Aliment Pharmacol Ther. 2007;25:941–7.

PubMed  CAS  Google Scholar 

Cuffari C, Dassopoulos T, Turnbough L, Thompson RE, Bayless TM. Thiopurine methyltransferase activity influences clinical response to azathioprine in inflammatory bowel disease. Clin Gastroenterol Hepatol. 2004;2:410–7.

PubMed  CAS  Google Scholar 

Osterman MT, Kundu R, Lichtenstein GR, Lewis JD. Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis. Gastroenterology. 2006;130:1047–53.

PubMed  CAS  Google Scholar 

Feng R, Guo J, Zhang SH, et al. Low 6-thioguanine nucleotide level: effective in maintaining remission in Chinese patients with Crohn’s disease. J Gastroenterol Hepatol. 2019;34:679–85.

PubMed  CAS  Google Scholar 

Andoh A, Tsujikawa T, Ban H, et al. Monitoring 6-thioguanine nucleotide concentrations in Japanese patients with inflammatory bowel disease. J Gastroenterol Hepatol. 2008;23:1373–7.

PubMed  CAS  Google Scholar 

Smith M, Blaker P, Patel C, et al. The impact of introducing thioguanine nucleotide monitoring into an inflammatory bowel disease clinic. Int J Clin Pract. 2013;67:161–9.

PubMed  CAS  Google Scholar 

Ribeiro AC, Gerheim PSAS, Chebli JMF, Nascimento JWL, Faria PP. The role of pharmacogenetics in the therapeutic response to thiopurines in the treatment of inflammatory bowel disease: a systematic review. J Clin Med. 2023;12:6742.

Goldberg R, Moore G, Cunningham G, et al. Thiopurine metabolite testing in inflammatory bowel disease. J Gastroenterol Hepatol. 2016;31:553–60.

PubMed  CAS  Google Scholar